ADJUVANT PAZOPANIB OR PLACEBO IN RESECTED STAGE I NSCLC PATIENTS: RESULTS OF THE NSCLC ADJUVANT RANDOMIZED PHASE II TRIAL (IFCT-0703) FROM THE FRENCH COLLABORATIVE INTERGROUP

被引：0
|
作者：
Besse, Benjamin [1 ]
Mazieres, Julien [2 ]
Ribassin-Majed, L. [3 ]
Barlesi, Fabrice [4 ]
Bennouna, Jaafar [5 ]
Gervais, Radj [6 ]
Moreau, Lionel
Berard, Henri [7 ]
Debieuvre, Didier
Molinier, Olivier [8 ]
Moro-Sibilot, Denis [9 ]
Souquet, Pierre-Jean [10 ]
Pignon, Jean-Pierre [3 ]
Amour, Elodie [11 ]
Celebic, A. [3 ]
Morin, Franck [11 ]
Milleron, Bernard [11 ]
Zalcman, Gerard [12 ]
Soria, Jean-Charles [1 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Univ Toulouse 3, Resp Med Serv, Hop Larrey, Chu Toulouse, F-31062 Toulouse, France
[3] Gustave Roussy, Biostat, Villejuif, France
[4] Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France
[5] Inst Cancerol Ouest, Gustave Roussy, France
[6] Ctr Francois Baclesse, Caen, France
[7] Hop Instruct Armees St Anne, Serv Pathol Resp, Toulon, France
[8] Le Mans Reg Hosp, Le Mans, France
[9] Unite Oncol Thorac Pneumol, Pierre Benite, France
[10] Pneumol Hcl, Paris, France
[11] Ifct, Paris, France
[12] Caen Univ Hosp, Caen, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
adjuvant; Non small cell lung cancer; angiogenic inhibitor; randomized phase II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO08.02
引用
收藏
页码：S301 / S301
页数：1
相关论文
共 39 条
  • [21] Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials
    Shu-Ling Zhang
    Xiao-Fang Yi
    Le-Tian Huang
    Li Sun
    Jie-Tao Ma
    Cheng-Bo Han
    BMC Cancer, 23
  • [22] A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer- pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial
    Saka, Hideo
    Kitagawa, Chiyoe
    Ichinose, Yukito
    Takenoyama, Mitsuhiro
    Ibata, Hidenori
    Kato, Tatsuo
    Takami, Koji
    Yamashita, Motohiro
    Maeda, Tadashi
    Takeo, Sadanori
    Ueda, Hitoshi
    Okabayashi, Kan
    Nagashima, Seiji
    Oka, Tadayuki
    Kouso, Hidenori
    Fukuyama, Seiichi
    Yoshimoto, Kentaro
    Shimokawa, Mototsugu
    Saito, Akiko M.
    Ito, Suminobu
    TRIALS, 2017, 18
  • [23] Patient-Reported Outcomes of Postoperative NSCLC Patients with or without Staged Chinese Herb Medicine Therapy during Adjuvant Chemotherapy (NALLC 2): A Randomized, Double-Blind, Placebo-Controlled Trial
    Zhang, Yi-lu
    Jiao, Li-jing
    Gong, Ya-bin
    Xu, Jian-fang
    Ni, Jian
    Shen, Xiao-yong
    Zhang, Jie
    Zhou, Di
    Qian, Cheng-xin
    Wang, Qin
    Yao, Jia-lin
    Yang, Wen-xiao
    Su, Ling-zi
    Wang, Li-yu
    Li, Jia-qi
    Yao, Yi-qin
    Zhang, Yuan-hui
    Wang, Yi-chao
    Chen, Zhi-wei
    Xu, Ling
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2024, 30 (11) : 963 - 973
  • [24] A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer
    Okarnoto, Tatsuro
    Yano, Tokujiro
    Shimokawa, Mototsugu
    Takeo, Sadanori
    Yamazaki, Koji
    Sugio, Kenji
    Takenoyama, Mitsuhiro
    Nagashima, Akira
    Tsukamoto, Shuichi
    Hamatake, Motoharu
    Yokoyama, Hideki
    Ueda, Hitoshi
    Motohiro, Akira
    Tagawa, Tetsuzo A.
    Shoj, Fumihiro
    Kometanie, Takuro
    Saito, Genkichi
    Fukuyamap, Yasuro
    Toyokawa, Gouji
    Osoegawa, Atsushi
    Emie, Yasunori
    Maeharaa, Yoshihiko
    LUNG CANCER, 2018, 124 : 255 - 259
  • [25] Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial
    Souquet, Pierre-Jean
    Audigier-Valette, Clarisse
    Molinier, Olivier
    Cortot, Alexis
    Margery, Jacques
    Moreau, Lionel
    Gervais, Radj
    Barlesi, Fabrice
    Pichon, Eric
    Zalcman, Gerard
    Dumont, Patrick
    Girard, Nicolas
    Poudenx, Michel
    Mazieres, Julien
    Cadranel, Jacques
    Debieuvre, Didier
    Dauba, Jerome
    Langlais, Alexandra
    Morin, Franck
    Moro-Sibilot, Denis
    Westeel, Virginie
    Perol, Maurice
    LUNG CANCER, 2022, 164 : 84 - 90
  • [26] Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503
    Kubota, Kaoru
    Kunitoh, Hideo
    Seto, Takashi
    Shimada, Naoki
    Tsuboi, Masahiro
    Ohhira, Tatsuo
    Okamoto, Hiroaki
    Masuda, Noriyuki
    Maruyama, Riichiroh
    Shibuya, Masahiko
    Watanabe, Koshiro
    LUNG CANCER, 2020, 141 : 32 - 36
  • [27] Impact of postoperative radiation therapy on survival in patients with complete resection and Stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) randomized trial
    Douillard, Jean-Yves
    Rosell, Rafael
    De Lena, Mario
    Riggi, Marcello
    Hurteloup, Patrick
    Mahe, Marc-Andre
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (03): : 695 - 701
  • [28] Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
    Lara, Primo N., Jr.
    Tangen, Catherine
    Heath, Elisabeth I.
    Gulati, Shuchi
    Stein, Mark N.
    Meng, Maxwell
    Alva, Ajjai Shivaram
    Pal, Sumanta K.
    Puzanov, Igor
    Clark, Joseph I.
    Choueiri, Toni K.
    Agarwal, Neeraj
    Uzzo, Robert
    Haas, Naomi B.
    Synold, Timothy W.
    Plets, Melissa
    Vaishampayan, Ulka N.
    Shuch, Brian M.
    Lerner, Seth
    Thompson, Ian M., Jr.
    Ryan, Christopher W.
    EUROPEAN UROLOGY, 2024, 86 (03) : 258 - 264
  • [29] Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301
    Norihito Okumura
    Junichi Soh
    Hiroyuki Suzuki
    Masao Nakata
    Toshiya Fujiwara
    Hiroshige Nakamura
    Makoto Sonobe
    Takuji Fujinaga
    Kazuhiko Kataoka
    Kenichi Gemba
    Masafumi Kataoka
    Katsuyuki Hotta
    Hiroshige Yoshioka
    Keitaro Matsuo
    Junichi Sakamoto
    Hiroshi Date
    Shinichi Toyooka
    BMC Cancer, 21
  • [30] Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301
    Okumura, Norihito
    Soh, Junichi
    Suzuki, Hiroyuki
    Nakata, Masao
    Fujiwara, Toshiya
    Nakamura, Hiroshige
    Sonobe, Makoto
    Fujinaga, Takuji
    Kataoka, Kazuhiko
    Gemba, Kenichi
    Kataoka, Masafumi
    Hotta, Katsuyuki
    Yoshioka, Hiroshige
    Matsuo, Keitaro
    Sakamoto, Junichi
    Date, Hiroshi
    Toyooka, Shinichi
    BMC CANCER, 2021, 21 (01)
1234